Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells

A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders

(2017) T.C. Theoharides et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury

(2016) Marika Cordaro et al.   JOURNAL OF NEUROTRAUMA

Metabolism and functions of lipids in myelin

(2015) Sebastian Schmitt et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

The Wnt Effector Transcription Factor 7-Like 2 Positively Regulates Oligodendrocyte Differentiation in a Manner Independent of Wnt/ -Catenin Signaling

(2015) E. Hammond et al.   JOURNAL OF NEUROSCIENCE

Promoting remyelination in multiple sclerosis: Current drugs and future prospects

(2015) David Kremer et al.   Multiple Sclerosis Journal

Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

(2015) Fadi J. Najm et al.   NATURE

Multiple sclerosis—a quiet revolution

(2015) Richard M. Ransohoff et al.   Nature Reviews Neurology

Promoting remyelination in multiple sclerosis: Current drugs and future prospects

(2015) David Kremer et al.   Multiple Sclerosis Journal

Activation of endogenous neural stem cells for multiple sclerosis therapy

(2015) Iliana Michailidou et al.   Frontiers in Neuroscience

Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-γ and alpha B-crystallin

(2014) Malika Bsibsi et al.   ACTA NEUROPATHOLOGICA

Targets of the humoral autoimmune response in multiple sclerosis

(2014) Judith Fraussen et al.   AUTOIMMUNITY REVIEWS

Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation

(2014) Irene Paterniti et al.   CNS & Neurological Disorders-Drug Targets

Harnessing the anti-inflammatory potential of palmitoylethanolamide

(2014) Mireille Alhouayek et al.   DRUG DISCOVERY TODAY

Multiple Sclerosis: Current Knowledge and Future Outlook

(2014) Christian P. Kamm et al.   EUROPEAN NEUROLOGY

Remyelinating strategies in multiple sclerosis

(2014) Felix Luessi et al.   Expert Review of Neurotherapeutics

Mammalian Target of Rapamycin Promotes Oligodendrocyte Differentiation, Initiation and Extent of CNS Myelination

(2014) S. E. Wahl et al.   JOURNAL OF NEUROSCIENCE

Balanced mTORC1 Activity in Oligodendrocytes Is Required for Accurate CNS Myelination

(2014) F. Lebrun-Julien et al.   JOURNAL OF NEUROSCIENCE

Remyelination in multiple sclerosis: Cellular mechanisms and novel therapeutic approaches

(2014) John A. Olsen et al.   JOURNAL OF NEUROSCIENCE RESEARCH

The Clinical Impact of Cerebellar Grey Matter Pathology in Multiple Sclerosis

(2014) Alfredo Damasceno et al.   PLoS One

Akt/mTOR signalling in myelination

(2013) Camilla Norrmén et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression

(2013) Rosalia Crupi et al.   CNS & Neurological Disorders-Drug Targets

Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype

(2013) Massimo Barbierato et al.   CNS & Neurological Disorders-Drug Targets

The Use of Flavonoids in Central Nervous System Disorders

(2013) C. Grosso et al.   CURRENT MEDICINAL CHEMISTRY

Mast cells, glia and neuroinflammation: partners in crime?

(2013) Stephen D. Skaper et al.   IMMUNOLOGY

Oligodendrocyte-microglia cross-talk in the central nervous system

(2013) Laura Peferoen et al.   IMMUNOLOGY

A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

(2013) Irene Paterniti et al.   Journal of Neuroinflammation

A regenerative approach to the treatment of multiple sclerosis

(2013) Vishal A. Deshmukh et al.   NATURE

Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities

(2013) I. Tabas et al.   SCIENCE

Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain

(2013) Stephen D. Skaper et al.   INFLAMMOPHARMACOLOGY

Cortical remyelination: A new target for repair therapies in multiple sclerosis

(2012) Ansi Chang et al.   ANNALS OF NEUROLOGY

Pathology of Multiple Sclerosis

(2012) Markus Kipp et al.   CNS & Neurological Disorders-Drug Targets

Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide

(2012) S. D. Skaper et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?

(2012) Melissa A. Brown et al.   Frontiers in Immunology

Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways

(2011) O Gomez et al.   BRITISH JOURNAL OF PHARMACOLOGY

Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation

(2011) Hebe M. Guardiola-Diaz et al.   GLIA

N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities

(2010) Stefania Petrosino et al.   BIOCHIMIE

Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats

(2009) Bei Xu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Activation of the Mammalian Target of Rapamycin (mTOR) Is Essential for Oligodendrocyte Differentiation

(2009) W. A. Tyler et al.   JOURNAL OF NEUROSCIENCE

Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination

(2009) S. P. Narayanan et al.   JOURNAL OF NEUROSCIENCE

Maturation-dependent sensitivity of oligodendrocyte lineage cells to apoptosis: implications for normal development and disease

(2008) B D Butts et al.   CELL DEATH AND DIFFERENTIATION

Assessment of luteolin (3′,4′,5,7-tetrahydroxyflavone) neuropharmacological activity

(2007) Miguel Coleta et al.   BEHAVIOURAL BRAIN RESEARCH